The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals.
ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist of toxic drugs attached by a so-called ‘linker’ molecule to an antibody that can guide them to tumor cells. This drug class has been researched for decades, but has only come into its own in the last few years with the rapid-fire approvals of drugs including Blenrep, Todelvy, Enhertu, and more.
“There is high momentum in the ADC space and it is exciting to see the increase in ADC approvals and to see that these molecules provide benefit for patients,” said Dominik Schumacher, CEO of the German ADC player Tubulis.